Advertisement
Dr. Joseph A. Mollica, Chairman of the Board and Acting Chief ExecutiveOfficer, Mr. Brian M. Posner, Executive Vice President and Chief FinancialOfficer, and Dr. Rene Belder, Senior Vice President, Clinical and RegulatoryAffairs, will host the call. Forward-looking and other material informationmay be discussed on this conference call.
Advertisement
A replay of the conference call can be accessed by dialing toll-free(888) 203-1112 in the U.S., or (719) 457-0820 outside the U.S. The access codefor the replay is 9717744. Replay of the webcast will also be accessible onPharmacopeia's website on the Investors page at www.pharmacopeia.com. Thereplays will be available for two weeks.
ABOUT PHARMACOPEIA
Pharmacopeia is a clinical development stage biopharmaceutical companydedicated to discovering and developing novel small molecule therapeutics toaddress significant medical needs. The company has a broad portfolio ofclinical and preclinical candidates under development internally or bypartners including eight clinical compounds in Phase 2 or Phase 1 developmentaddressing multiple indications including hypertension, diabetic nephropathy,muscle wasting, inflammation and respiratory disease. The company isleveraging its fully integrated drug discovery platform to sustain the growthof its development pipeline. Pharmacopeia has established strategic allianceswith major pharmaceutical and biotechnology companies, including Bristol-MyersSquibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and WyethPharmaceuticals. For more information please visit the company's website athttp://www.pharmacopeia.com.
This press release, and oral statements made with respect to informationcontained in this press release, constitute forward-looking statements withinthe meaning of the Private Securities Litigation Reform Act of 1995. Suchforward-looking statements include those which express plan, anticipation,intent, contingency or future development and/or otherwise are not statementsof historical fact. These statements are based upon management's currentexpectations and are subject to risks and uncertainties, known and unknown,which could cause actual results and developments to differ materially fromthose expressed or implied in such statements. Further information about theseand other relevant risks and uncertainties may be found in Pharmacopeia'sReports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and ExchangeCommission. Pharmacopeia urges you to carefully review and consider thedisclosures found in its filings which are available in the SEC EDGAR databaseat http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com.All forward-looking statements in this press release and oral statements madewith respect to information contained in this press release are qualifiedentirely by the cautionary statements included in this press release and suchfilings. These risks and uncertainties could cause actual results to differmaterially from results expressed or implied by such forward-lookingstatements. These forward-looking statements speak only as of the date of thispress release. Pharmacopeia undertakes no obligation to (and expresslydisclaims any such obligation to) publicly update or revise the statementsmade herein or the risk factors that may relate thereto whether as a result ofnew information, future events, or otherwise.Date: May 7, 2008 Time: 5:00 p.m. EDT Webcast: Accessible via the company's website at http://www.pharmacopeia.com
